Notice: Users may be experiencing issues with displaying some pages on stanfordhealthcare.org. We are working closely with our technical teams to resolve the issue as quickly as possible. Thank you for your patience.
 

Learn about the flu shot, COVID-19 vaccine, and our masking policy »

Stanford Health Care

Panel of Prototypical Raltegravir-Resistant Infectious Molecular Clones in a Novel Integrase-Deleted Cloning Vector ANTIMICROBIAL AGENTS AND CHEMOTHERAPY Reuman, E. C., Bachmann, M. H., Varghese, V., Fessel, W. J., Shafer, R. W. 2010; 54 (2): 934-936

Abstract

We created an HIV-1 cloning vector, pNL4.3DeltaIN, to generate recombinant infectious molecular clones for analysis of patient-derived HIV-1 integrase coding regions. Using this vector, we constructed a panel of clinically derived viruses with the canonical patterns of raltegravir resistance mutations and submitted the panel to the NIH AIDS Research and Reference Reagent Program. Investigational integrase inhibitors with activity against these clones are likely to retain activity against the most clinically relevant raltegravir-resistant variants.

View details for DOI 10.1128/AAC.01345-09

View details for Web of Science ID 000273860600051

View details for PubMedID 19917747

View details for PubMedCentralID PMC2812164